Shi‐Ming Lin

3.4k total citations
73 papers, 2.3k citations indexed

About

Shi‐Ming Lin is a scholar working on Hepatology, Epidemiology and Oncology. According to data from OpenAlex, Shi‐Ming Lin has authored 73 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Hepatology, 42 papers in Epidemiology and 16 papers in Oncology. Recurrent topics in Shi‐Ming Lin's work include Hepatocellular Carcinoma Treatment and Prognosis (35 papers), Hepatitis B Virus Studies (31 papers) and Liver Disease Diagnosis and Treatment (29 papers). Shi‐Ming Lin is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (35 papers), Hepatitis B Virus Studies (31 papers) and Liver Disease Diagnosis and Treatment (29 papers). Shi‐Ming Lin collaborates with scholars based in Taiwan, United States and China. Shi‐Ming Lin's co-authors include Yun‐Fan Liaw, Rong‐Nan Chien, Yun‐Fan Liaw, I‐Shyan Sheen, I-Shyan Sheen, Deng‐Yn Lin, Chia‐Ming Chu, Ming‐Lung Yu, Chuan–Mo Lee and Ming‐Whei Yu and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Hepatology.

In The Last Decade

Shi‐Ming Lin

70 papers receiving 2.2k citations

Peers

Countries citing papers authored by Shi‐Ming Lin

Since Specialization

Citations

This map shows the geographic impact of Shi‐Ming Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shi‐Ming Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shi‐Ming Lin more than expected).

Fields of papers citing papers by Shi‐Ming Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shi‐Ming Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shi‐Ming Lin. The network helps show where Shi‐Ming Lin may publish in the future.

Co-authorship network of co-authors of Shi‐Ming Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Shi‐Ming Lin. A scholar is included among the top collaborators of Shi‐Ming Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shi‐Ming Lin. Shi‐Ming Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comparing Lenvatinib/Pembrolizumab with Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma: A Real-World Experience with Propensity Score Matching Analysis 2024 ·Cancers ·(unknown), (unknown), Wei Teng, (unknown), Wei‐Ting Chen, (unknown), (unknown), (unknown), Chen‐Chun Lin, Chun‐Yen Lin, Shi‐Ming Lin, (unknown), (unknown)	4
2	Absence of Survival Impact from Hepatitis During Immunotherapy in 193 Patients with Advanced Hepatocellular Carcinoma – An Observational Study from Taiwan 2024 ·Journal of Hepatocellular Carcinoma ·(unknown), (unknown), (unknown), (unknown), Shi‐Ming Lin, Chao‐Wei Lee, Ming‐Chin Yu, Wei‐Chen Lee, (unknown), Chia‐Hsun Hsieh	0
3	Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma– with Emphasis on Locoregional Therapy for Oligoprogression 2024 ·Liver Cancer ·Tsung‐Hao Liu, San‐Chi Chen, Kun‐Ming Rau, Li‐Chun Lu, (unknown), Yung‐Yeh Su, Wei Teng, Shiue‐Wei Lai, (unknown), (unknown), Pei‐Chang Lee, (unknown), Chien‐Hung Chen, Chih‐Hung Hsu, Shi‐Ming Lin, Yi‐Hsiang Huang, Li‐Tzong Chen, Ann‐Lii Cheng, Ying‐Chun Shen	7
4	Subsequent locoregional therapy prolongs survival in progressive hepatocellular carcinoma patients under lenvatinib treatment 2024 ·Journal of the Formosan Medical Association ·(unknown), Wei Teng, Wen‐Juei Jeng, Chen‐Chun Lin, Chun‐Yen Lin, Shi‐Ming Lin, I‐Shyan Sheen	2
5	GALNT14 genotype-guided chemoembolization plus sorafenib therapy in hepatocellular carcinoma: a randomized trial 2022 ·Hepatology International ·Wei‐Ting Chen, Shi‐Ming Lin, Wei‐Chen Lee, Ting-Jung Wu, Chen‐Chun Lin, Chien‐Heng Shen, Ming‐Ling Chang, Chih‐Lang Lin, Chau‐Ting Yeh	11
6	Proton Beam Therapy in Managing Unresectable Hepatocellular Carcinoma with Bile Duct Invasion 2022 ·Cancers ·(unknown), (unknown), (unknown), Cheng‐En Hsieh, Jeng‐Hwei Tseng, (unknown), (unknown), Joseph Tung‐Chieh Chang, Kun‐Ming Chan, Shi‐Ming Lin, Chen‐Chun Lin, Wei‐Ting Chen, Chen Wy, Bing‐Shen Huang	3
7	Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first‐line treatment for unresectable hepatocellular carcinoma 2022 ·Cancer Medicine ·(unknown), Wei Teng, (unknown), Wen‐Juei Jeng, (unknown), (unknown), Wei‐Ting Chen, (unknown), Chia‐Hsun Hsieh, (unknown), (unknown), Chen‐Chun Lin, Chun‐Yen Lin, Shi‐Ming Lin	17
8	AXL and MET in Hepatocellular Carcinoma: A Systematic Literature Review 2022 ·Liver Cancer ·Chih‐Hung Hsu, Yi‐Hsiang Huang, Shi‐Ming Lin, Chiun Hsu	21
9	Systemic Treatment of Advanced Unresectable Hepatocellular Carcinoma after First-Line Therapy: Expert Recommendations from Hong Kong, Singapore, and Taiwan 2022 ·Liver Cancer ·Thomas Yau, David Tai, Stephen L. Chan, Yi‐Hsiang Huang, Su Pin Choo, Chiun Hsu, Tan To Cheung, Shi‐Ming Lin, Wei Peng Yong, Joycelyn Jie Xin Lee, Thomas W. T. Leung, (unknown), Cynthia Yeung, (unknown), (unknown), Ann‐Lii Cheng, Li‐Tzong Chen	16
10	Functional Genomics Identifies Hepatitis-Induced STAT3–TYRO3–STAT3 Signaling as a Potential Therapeutic Target of Hepatoma 2019 ·Clinical Cancer Research ·(unknown), (unknown), Ming‐Chin Yu, (unknown), Tse‐Ching Chen, Wen‐Yu Chuang, (unknown), Chen‐Chun Lin, Shi‐Ming Lin, Sen‐Yung Hsieh	13
11	Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Impact of Early Response to 4 Weeks of Treatment 2015 ·Liver Cancer ·Chen‐Chun Lin, Chien‐Fu Hung, Wei‐Ting Chen, Shi‐Ming Lin	41
12	Radiofrequency ablation assisted by real‐time virtual sonography for hepatocellular carcinoma inconspicuous under sonography and high‐risk locations 2015 ·The Kaohsiung Journal of Medical Sciences ·Cheng‐Han Lee, Wei‐Ting Chen, Chen‐Chun Lin, Wei Teng, Shi‐Ming Lin, (unknown)	9
13	Combining radiofrequency ablation and ethanol injection may achieve comparable long‐term outcomes in larger hepatocellular carcinoma (3.1–4 cm) and in high‐risk locations 2014 ·The Kaohsiung Journal of Medical Sciences ·(unknown), Chen‐Chun Lin, Wei‐Ting Chen, Shi‐Ming Lin	13
14	Prospective Study of a ‘Popping' Sound during Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma 2010 ·Journal of Vascular and Interventional Radiology ·(unknown), Chen‐Chun Lin, Chun‐Jung Lin, Wei‐Ting Chen, Shi‐Ming Lin	16
15	Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1386‐patient study from Taiwan 2007 ·Alimentary Pharmacology & Therapeutics ·Jee‐Fu Huang, Ming‐Lung Yu, (unknown), Chia‐Yen Dai, (unknown), (unknown), John Wang, Sheng‐Nan Lu, I‐Shyan Sheen, Shi‐Ming Lin, Wan‐Long Chuang, Yun‐Fan Liaw	55
16	Association of cytokine and DNA repair gene polymorphisms with hepatitis B-related hepatocellular carcinoma 2005 ·International Journal of Epidemiology ·Chun‐Chieh Chen, Shi‐Yi Yang, Chun‐Jen Liu, Chih‐Lin Lin, Yun‐Fan Liaw, Shi‐Ming Lin, Shou‐Dong Lee, Pei‐Jer Chen, Chien‐Jen Chen, Ming‐Whei Yu	91
17	Prospective randomized controlled study of interferon‐alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors 2004 ·Cancer ·Shi‐Ming Lin, Chun‐Jung Lin, Chao‐Wei Hsu, Dar‐In Tai, I‐Shyan Sheen, Deng‐Yn Lin, Yun‐Fan Liaw	106
18	Increased risk for hepatitis B-related liver cirrhosis in relatives of patients with hepatocellular carcinoma in northern Taiwan 2002 ·International Journal of Epidemiology ·Ming‐Whei Yu, H. C. Chang, Pei‐Jer Chen, Chun‐Jen Liu, Yun‐Fan Liaw, Shi‐Ming Lin, Shou‐Dong Lee, Shee‐Chan Lin, Chih‐Lin Lin, Chien‐Jen Chen	25
19	Cytologic Changes in Hepatocellular Carcinoma After Percutaneous Acetic Acid Injection 2000 ·Acta Cytologica ·Shi‐Ming Lin, (unknown), Deng‐Yn Lin, Chun‐Jung Lin, (unknown), Chien‐Fu Hung	9
20	Beneficial effect of prednisolone withdrawal followed by human lymphoblastoid interferon on the treatment of chronic type B hepatitis in Asians: a randomized controlled trial 1994 ·Journal of Hepatology ·Yun‐Fan Liaw, Shi‐Ming Lin, Tong‐Jong Chen, Rong‐Nan Chien, I-Shyan Sheen, (unknown)	60

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact